A physician-validated, board-style question from the Active Transport QBank. Try it, then check the reasoning for every option.
A 5-year-old boy is brought in by his mother with reports of trouble at school. Teachers report that for the last 6 months he has been having difficulty finishing tasks, is easily distracted, frequently does not listen, commonly fails to finish schoolwork, has not been able to complete any of the class projects this year, and frequently loses school books and supplies. Teachers also say that he constantly fidgets, often leaves his seat without permission, has trouble being quiet, talks excessively, frequently interrupts his classmates when trying to answer questions, and has difficulty waiting in line. The mother states that she has also been noticing similar behaviors at home and that his symptoms have been affecting him negatively academically and socially. The patient has no significant past medical history. The patient is in the 90th percentile for height and weight and has been meeting all the developmental milestones. He is afebrile, and his vital signs are within normal limits. A physical examination is unremarkable. Which of the following medications is a first-line treatment for this patient’s most likely diagnosis?
-
A
AtomoxetineIncorrect. Atomoxetine is a second-line non-stimulant SNRI for ADHD; used when stimulants are contraindicated or poorly tolerated.
-
B
MethylphenidateCorrect. methylphenidate (a stimulant) is first-line pharmacotherapy for ADHD in school-age children.
-
C
ClonidineIncorrect. Clonidine is an alpha-2 agonist used as adjunct or second-line, particularly when comorbid tics or sleep disturbance are present.
-
D
GuanfacineIncorrect. Guanfacine is another alpha-2 agonist used as second-line or adjunct, not first-line.
-
E
RisperidoneIncorrect. Risperidone is an atypical antipsychotic used for irritability in autism spectrum disorder and psychotic disorders; it is not a first-line treatment for ADHD.
↑ Tap an answer to reveal the reasoning
Answer: B. A 5-year-old boy with greater than 6 months of inattention (difficulty finishing tasks, distractibility, not listening, losing items, incomplete schoolwork) and hyperactivity-impulsivity (fidgeting, leaving seat, talking excessively, interrupting, difficulty waiting) across multiple settings (school and home) and impairing academic and social function meets DSM-5 criteria for attention-deficit/hyperactivity disorder (ADHD), combined presentation.
First-line pharmacotherapy for ADHD in children ages 6 and older is a stimulant medication: methylphenidate or amphetamine derivatives. Stimulants increase synaptic dopamine and norepinephrine in the prefrontal cortex by blocking reuptake (and, for amphetamines, also promoting release), improving attention, executive function, and impulse control. Methylphenidate is the most commonly chosen first-line agent and has the largest evidence base.
Non-stimulants like atomoxetine (a selective norepinephrine reuptake inhibitor) and alpha-2 agonists (clonidine, guanfacine) are second-line or used when stimulants are contraindicated, ineffective, or cause unacceptable side effects (insomnia, growth suppression, tics). For preschoolers (under 6), behavioral therapy is first-line before pharmacotherapy.
**Why each option:**
**A.** Atomoxetine is a second-line non-stimulant SNRI for ADHD; used when stimulants are contraindicated or poorly tolerated.
**B.** Correct: methylphenidate (a stimulant) is first-line pharmacotherapy for ADHD in school-age children.
**C.** Clonidine is an alpha-2 agonist used as adjunct or second-line, particularly when comorbid tics or sleep disturbance are present.
**D.** Guanfacine is another alpha-2 agonist used as second-line or adjunct, not first-line.